Kobayashi K, Ishii M, Shiina M, Ueno Y, Kondo Y, Kanno A, Miyazaki Y, Yamamoto T, Kobayashi T, Niitsuma H, Kikumoto Y, Takizawa H, Shimosegawa T
Tohoku University School of Health Sciences and Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation, Sendai, Japan.
Clin Exp Immunol. 2005 Jul;141(1):81-8. doi: 10.1111/j.1365-2249.2005.02018.x.
Differences in cytotoxic T lymphocyte activity in hepatitis C virus infection may account for the outcome of interferon monotherapy. To investigate this hypothesis, we analysed the response of peripheral CD8(+) T cells that recognized epitopes presented by HLA-A*2402. We synthesized HLA/beta2-microglobulin/peptide complexes using two epitopes. Production of interferon-gamma by CD8(+) T cells in response to plastic-bound monomeric HLA/peptide complex was observed frequently in sustained virus responders (SVR) (n = 13) against all the peptides, NS31296-1304 (the percentage of responding patients, 61.5%) and core 129-137 (53.8%), while no interferon-gamma production was observed in non-responders (NR) (n = 13) for any of the peptides. Tetramer-staining showed the presence of CD8(+) T cells specific for all the peptides except NS31296-1304 in two SVR at the end of interferon monotherapy, although hardly any such cells were found in four NR. Specific killing was observed against peptides NS31296-1304 (3/4) and core 129-137 (1/4) in sustained responders but none in non-responders. These results suggest that the responses of cytotoxic T lymphocytes (CTLs) were induced during interferon therapy in these patients and that interferon-gamma production by CD8(+) T lymphocytes against HCV NS31296-1304 and core 129-137 are well maintained in patients with SVR compared with those with NR. These findings emphasize the importance of the CD8(+) T cell response in controlling HCV infection.
丙型肝炎病毒感染中细胞毒性T淋巴细胞活性的差异可能是干扰素单一疗法疗效不同的原因。为了验证这一假设,我们分析了识别由HLA-A*2402呈递表位的外周血CD8(+) T细胞的反应。我们使用两个表位合成了HLA/β2-微球蛋白/肽复合物。在持续病毒应答者(SVR,n = 13)中,针对所有肽段(NS3 1296-1304,应答患者百分比为61.5%;核心区129-137,53.8%),经常观察到CD8(+) T细胞对塑料结合的单体HLA/肽复合物产生γ干扰素,而在无应答者(NR,n = 13)中,未观察到任何肽段诱导产生γ干扰素。四聚体染色显示,在干扰素单一疗法结束时,两名SVR患者中存在除NS3 1296-1304外对所有肽段特异的CD8(+) T细胞,而在四名NR患者中几乎未发现此类细胞。在持续应答者中观察到对肽段NS3 1296-1304(3/4)和核心区129-137(1/4)的特异性杀伤,而在无应答者中未观察到。这些结果表明,这些患者在干扰素治疗期间诱导了细胞毒性T淋巴细胞(CTL)反应,与NR患者相比,SVR患者中CD8(+) T淋巴细胞针对HCV NS3 1296-1304和核心区129-137产生γ干扰素的能力得到了良好维持。这些发现强调了CD8(+) T细胞反应在控制HCV感染中的重要性。